| Basics |
Veracyte, Inc.
Veracyte Inc is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The Company's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier.
|
| IPO Date: |
October 30, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.88B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.57 | 2.53%
|
| Avg Daily Range (30 D): |
$0.64 | 1.90%
|
| Avg Daily Range (90 D): |
$0.57 | 1.95%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.39M |
| Avg Daily Volume (30 D): |
.65M |
| Avg Daily Volume (90 D): |
.93M |
| Trade Size |
| Avg Trade Size (Sh.): |
63 |
| Avg Trade Size (Sh.) (30 D): |
44 |
| Avg Trade Size (Sh.) (90 D): |
55 |
| Institutional Trades |
| Total Inst.Trades: |
3,379 |
| Avg Inst. Trade: |
$2.71M |
| Avg Inst. Trade (30 D): |
$3.99M |
| Avg Inst. Trade (90 D): |
$4.78M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.95M |
| Avg Closing Trade (30 D): |
$6.23M |
| Avg Closing Trade (90 D): |
$8.06M |
| Avg Closing Volume: |
134.06K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.01
|
$.09
|
|
Diluted EPS
|
|
$-.01
|
$.09
|
|
Revenue
|
$
|
$ 130.16M
|
$ 114.47M
|
|
Gross Profit
|
$
|
$ 89.77M
|
$ 79.51M
|
|
Net Income / Loss
|
$
|
$ -.98M
|
$ 7.05M
|
|
Operating Income / Loss
|
$
|
$ -5.27M
|
$ 2.9M
|
|
Cost of Revenue
|
$
|
$ 40.4M
|
$ 34.97M
|
|
Net Cash Flow
|
$
|
$ 33.39M
|
$ -52.87M
|
|
PE Ratio
|
|
|
|
|
|
|
